ArticleThe Journal of clinical endocrinology and metabolism2025
TSH Receptor Antibody Test Utilization Patterns From a National Reference Laboratory: TRAb, TSI, or Both?
Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Early predictors of 6-month thyroid-stimulating antibody levels after radioactive iodine therapy for Graves' disease: implications for pregnancy planning.Endocrine journal · 2026Article
- TSH Receptor Antibody Test Utilization Patterns From a National Reference Laboratory: TRAb, TSI, or Both?The Journal of clinical endocrinology and metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextThere are currently 2 classes of thyroid-stimulating hormone receptor (TSHR) antibody assays, namely TSHR antibody (TRAb) assays and thyroid-stimulating immunoglobulin (TSI) assays. Clinical guidelines do not currently specify appropriate use of TSHR autoantibody tests in the diagnosis of hyperthyroidism, which may result in paired orders for both tests with the possibility of discordant results and excessive costs.
objectiveThis work aimed to evaluate the clinical and analytical redundancy of paired TSHR autoantibody testing-specifically TRAb and TSI assays-in the diagnosis of autoimmune-mediated hyperthyroidism, by analyzing the frequency of paired orders, assay concordance, and clinical correlation across a large cohort of patient encounters.
methodsOver 189 000 patient encounters with TRAb and TSI bioassay (TSI-BA) or TSI bridge immunoassay (TSI-Br) test orders were examined to assess the frequency of paired orders and qualitative agreement of TRAB/TSI. A chart review was performed on a subset of patients for clinical correlation. Lastly, a cost analysis was performed to estimate the financial burden of unnecessary paired testing.
resultsTRAb and TSI were co-ordered on the same encounter in 14.3% of TRAb/TSI-BA orders and 17.4% of TRAb/TSI-Br orders. Qualitative comparison showed discordance in 12.5% (1590) of TRAb and TSI-BA paired orders and 6.6% (1149) of TRAb and TSI-Br paired orders. Based on patient free thyroxine and TSH concentrations and disease status, the TSI assays aligned better with hyperthyroidism and confirmed Graves disease diagnoses. Paired orders resulted in a 31% to 325% increase in potentially unnecessary testing costs.
conclusionWe observed good clinical and analytical agreement between TRAb and TSI assays, suggesting that paired orders for TRAb and TSI are redundant in the assessment of autoimmune-mediated hyperthyroidism. Use of a single test to assess TRAb would be appropriate in most scenarios and may lead to considerable savings of health care dollars.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.